266. Familial mediterranean fever
27 clinical trials,   23 drugs   (DrugBank: 6 drugs),   14 drug target genes,   57 drug target pathways

Searched query = "Familial mediterranean fever"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2016-004505-13-DE
(EUCTR)
27/11/201721/08/2017Tocilizumab for the Treatment of Familial Mediterranean FeverTocilizumab for the Treatment of Familial Mediterranean Fever – A randomized, doubleblind, phase II proof of concept study-TOFFIFE - Tocilizumab for the Treatment of Familial Mediterranean Fever Adult patients with Familial Mediterranean Fever, who have active disease
MedDRA version: 20.0;Level: PT;Classification code 10016207;Term: Familial mediterranean fever;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: RoActemra® 20mg/ml Konzentrat
INN or Proposed INN: INN-Tocilizumab
Other descriptive name: TOCILIZUMAB
University Hospital TuebingenNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
30Phase 2Germany